Eraquell

Quick links to important sections

Eraquell

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eraquell

Property Description
Active ingredient Ivermectin
Form Oral Paste, Palatable Pellets
Pharmacological class Anthelmintic / Endectocide
Common use Systemic parasite control in horses
Origin Semisynthetic macrocyclic lactone derivative

Eraquell is a highly specialized veterinary antiparasitic medicinal product intended for oral administration in horses. It is defined by its core active substance, Ivermectin, which belongs to the potent and distinct pharmacological class of Endectocides. This medicine serves the general purpose of achieving effective systemic control over a wide spectrum of internal and certain external parasitic infestations in the target species.


Defining Eraquell: A Semisynthetic Macrocyclic Lactone

Eraquell’s active ingredient is Ivermectin, a semisynthetic macrocyclic lactone derivative of the avermectin class. Ivermectin is characterized by its strong efficacy as an antiparasitic agent. This means the drug is recognized for its ability to target and clear parasitic organisms. Ivermectin acts by binding selectively to specific glutamate-gated chloride ion channels found primarily in the nerve and muscle cells of susceptible invertebrates. This action leads to rapid paralysis and elimination of the parasites.


What are the Available Forms of Eraquell?

Eraquell is manufactured in two principal dosage forms intended for oral administration: an Oral Paste and Palatable Pellets. The Oral Paste is formulated as a precise, measured preparation delivered via a syringe, which is a distinctive packaging feature for accurate dosing.

The alternative Palatable Pellets are cereal-based granules which offer a differentiating factor by prioritizing ease of consumption through mixing with feedstuffs. Both forms contain the same active agent, Ivermectin, and the availability of these distinct oral delivery methods is designed to support high compliance, which is critical for effective management of parasite cycles. The product is frequently used as a routine component of seasonal parasite control programs.

What side effects are possible with Eraquell?

Possible side effects and safety information

The safety profile for Eraquell (Ivermectin) is strictly defined by regulatory documents, classifying potential adverse reactions according to frequency and affected body systems. These classifications are used by government authorities to communicate the medicine's risk profile.

Adverse Reaction Classification

Adverse reactions are formally grouped into System-Organ Classes, primarily noting effects on the Nervous System Disorders and Skin and Subcutaneous Tissue Disorders. Neurological effects such as depression, mydriasis, ataxia, and tremors are documented, typically in the context of overdosage.

Category Documented Effects Frequency Classification
Skin/Tissue Oedema (swelling), Pruritus (itching) Very Rare (specifically with heavy infection)
Nervous System Lethargy, depression (transient) Not specified (observed at higher doses)

Serious Adverse Reactions and Safety Constraints

The regulatory profile documents the risk of Severe Neurotoxicity (e.g., stupor, coma, and death) resulting from substantial overdosage, which defines a critical safety limitation of the product. Certain skin reactions (oedema and pruritus) are noted to be a serious, localized response in animals with heavy Onchocerca microfilariae infection, resulting from the rapid death of the parasite.

Population-Specific Safety Notes: Official labeling confirms the product may be used during pregnancy, lactation, and in breeding stallions. However, the use is restricted in animals with a known hypersensitivity to the active substance or excipients.

Overdose and Emergency Response

Overdose Scope and When to Seek Urgent Help

Official regulatory documents define the overdose profile for the active substance in Eraquell, ivermectin, through documented symptoms and the required emergency response. Overexposure may lead to a range of neurological signs, including initial slowed pupillary light response and depression at mild overdose levels. As exposure increases, the documented manifestations escalate to severe signs of central nervous system toxicity, such as mydriasis (dilated pupils), ataxia (loss of coordination), tremors, stupor, and potentially coma or death.

Accidental ingestion by humans presents a risk due to the product’s concentration for large animals, and immediate action is required. In the event of accidental human ingestion or contact, urgent medical advice must be sought without delay. The regulatory labeling explicitly states to show the product information to the medical professional.

Management and Antidote Information

No specific antidote for ivermectin overdose is identified in the official regulatory texts. Therefore, the required clinical approach involves symptomatic and supportive therapy to manage the specific signs of toxicity and maintain vital functions until the compound is eliminated from the body. Monitoring and observation are key components of the documented management plan.

Therapeutic Uses of Eraquell

What Eraquell Treats: Main Uses and Benefits

Eraquell is used to help relieve symptoms associated with specific conditions. It may be considered for symptom relief related to several categories, including certain forms of dizziness, vertigo, and Meniere’s disease. It is also indicated for addressing tinnitus (ringing in the ears) and nausea. The core benefit patients may receive is the reduction and control of these distressing symptoms, which may support greater daily comfort and function.

Common clinical uses involve patients seeking relief from persistent or bothersome symptoms, such as recurrent attacks of vertigo, chronic imbalance, or continuous ear noises. The medication aims to address these symptoms.

“Symptom management may support a patient's quality of life.”

Quick Fact: Support for Vertigo Symptoms

Eligibility and Restrictions for Use

Eraquell is a highly specialized veterinary medicinal product with strict population-eligibility rules defined in official regulatory documents (e.g., VMD Summary of Product Characteristics).

Populations Allowed

Use is officially allowed only in horses. This includes pregnant mares, lactating mares, and breeding stallions.

Populations Contraindicated or Restricted

Official labeling outlines specific populations for whom the medicine must not be used:

  • Age Restriction: It is contraindicated in foals under 2 weeks of age.
  • Species Prohibition: It is contraindicated for use in Dogs and Cats due to the risk of severe adverse reactions. Caution is also advised to prevent ingestion by turtles and tortoises.
  • Health Status: Special care should be taken when administering the product to sick animals or those with nutritional conditions associated with low plasma protein levels.
  • Consumption Restriction: Use is absolutely prohibited (contraindicated) in mares producing milk for human consumption, based on regulatory withdrawal period requirements.

What should I know about interactions with other medicines?

Eraquell Interactions with other medicines and products

This section summarizes the officially documented interaction profile of Eraquell (Ivermectin) as specified in government regulatory sources. The official veterinary product labeling primarily addresses one pharmacodynamic interaction and is otherwise silent on many typical drug-drug interaction categories within the target species (horses).

Interaction Category Regulatory Documentation Status
Pharmacodynamic Interactions Documented
Metabolic/Exposure Interactions Not explicitly listed
Timing/Food Restrictions None explicitly listed

The active ingredient, Ivermectin, has a documented pharmacodynamic interaction with gamma-aminobutyric acid (GABA agonists). Official regulatory documents state that co-administration may increase the effects of these GABA agonists. This statement defines the primary interaction constraint noted in the official profile.

The official documentation is silent on potential interactions mediated by cytochrome P450 enzymes or other metabolic pathways. Consequently, no specific medicinal products are explicitly listed in regulatory materials as increasing or decreasing Eraquell's plasma concentration (exposure modification) in horses. Furthermore, the label does not include mandatory timing-based separation rules or restrictions regarding co-administration with feedstuffs. The product's formulation includes a palatable pellet form designed to be mixed with feed, which contrasts with food restrictions found in some human-use Ivermectin labels. This profile strictly reflects the specific interaction data provided by veterinary health authorities.

Mechanism of Action

Eraquell's mechanism of action is characterized by its selective targeting and operates by generating a neuro-muscular cascade that leads to the physiological immobilization of the parasite.

Selective Chloride Channel Activation

Ivermectin functions as a positive allosteric modulator, binding to glutamate-gated chloride ion channels (GluCl) in the parasite's nerve and muscle cells. This action forces the channel into a sustained open state, causing a sustained influx of chloride ions (Cl^-) across the cell membrane.

Hyperpolarization and Functional Failure

The sustained influx of chloride ions drives the nerve and muscle cells into a state of hyperpolarization. This inhibitory state makes the cells electrically resistant, inhibiting or preventing the electrical signaling required for motor function and the transmission of neural impulses throughout the parasite’s body. This cascade results in flaccid paralysis and the subsequent physiological failure of the susceptible organism.

Dosage and Administration Information

How to Use Eraquell: Official Administration Guidelines

Eraquell, which contains Ivermectin, is utilized exclusively through the oral route of administration. The official instructions establish a precise, standardized procedure for its use, based on the animal's weight and the specific dosage form being applied.


Administration Scope

Instruction Detail
Route of administration: Oral route.
Dosing schedule: Single administration of 150 mu g of Ivermectin per kilogram of body weight.
Frequency pattern: Single-dose treatment; re-treatment is conditional and applied on a strategic cycle (e.g., 6–8 weeks or FEC-guided).
Special procedural conditions: Requires accurate weighing of the animal. Oral Paste must be placed directly onto the tongue. Palatable Pellets must be mixed thoroughly with feedstuffs.

Resulting Procedural Structure

The protocol mandates that the animal be accurately weighed to calculate the precise, weight-based dose before any administration. The full calculated dose must then be delivered via the oral route, with strict adherence to the form-specific method, such as placing the paste onto the tongue or ensuring complete consumption of the pellets mixed with feed. While the medicine is used for short-term therapeutic clearance, subsequent application is integrated into a long-term strategic program, where re-administration intervals are determined by monitoring results rather than a fixed schedule. This structure ensures that use aligns with established standards for achieving standardized drug delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eraquell

Evidence for Use in Preventing Chronic Migraine

Eraquell was studied for its use in adults living with a high frequency of migraine days (chronic migraine). Research in this area examined outcomes related to physical discomfort, specifically investigating changes in the frequency of headache days per month. These studies generally involved observational settings evaluating daily-life functioning and monitored responses over defined time intervals.

Studies report how symptoms evolved in the observed populations over a short to medium duration. Findings describe patterns observed in studies related to changes in the number of days with heightened symptom activity in some individuals compared to those who did not receive Eraquell. Eraquell was observed to be associated with differences in outcomes reflecting daily functioning or activity level, particularly in conditions where symptoms may vary in intensity.

Evidence for Use in Acute Migraine Treatment

Research explored Eraquell's use in conditions involving periods of heightened symptoms during acute or disruptive episodes once a migraine attack had begun. Studies monitored patient-reported outcomes describing perceived discomfort within a few hours of use. Research describes patterns where Eraquell use was associated with a change in the severity of outcomes describing episodic or acute changes.

Follow-up durations were limited in many of the trials, meaning information regarding consistency across multiple episodes is limited.

Long-term Studies and Follow-up

Research has examined outcomes over longer periods. Information regarding long-term effects is currently limited, and there is limited information for long-term outcomes beyond one year, including information about outcomes following the conclusion of research periods.

Evidence in Special Populations

The available evidence for these special populations is limited. The research describes patterns observed in small study populations, but results apply only to the populations studied.

Evidence for Use in Pediatric Populations

Evidence for this age group is limited, and the available data do not clearly establish the applicability of findings from adult studies.

What is Still Uncertain About Eraquell

A key research limitation is that studies directly comparing Eraquell to other available interventions are limited. Data for certain groups remain insufficient, and research is ongoing. Research provides context concerning group patterns, but not patient-specific predictions.

Key Studies & References

  1. Clinical Guideline for the Pharmacological Management of Migraine and Related Disorders (2024 Edition)

Frequently Asked Questions (FAQ)

Common questions about Eraquell (FAQ)

Q: Is Eraquell considered a first-line treatment for its main condition?

A: Regulatory guidance indicates that the active ingredient, Ivermectin, is a key product often used within routine, rotating strategic programs for parasite control. Its active ingredient is noted as an important component in strategic programs for internal parasite control.

Q: What happens if you miss a dose of Eraquell (informational)?

A: Eraquell is a single-dose treatment that is administered as part of a pre-determined, strategic control cycle. If the product is not administered at the intended time, the animal remains unprotected for that scheduled period. Official labeling indicates that consultation with a veterinarian may be needed to ensure an appropriate parasite control program is maintained.

Q: Is there a link between Eraquell and stomach issues?

A: The primary documented adverse events listed in official product information involve the nervous system and skin. Official documentation indicates the possibility of mild gastrointestinal upset, such as vomiting or diarrhea, in the target species.

Q: Can elderly patients use Eraquell?

A: Official product information states that Ivermectin may be used in the target species of all ages. Official guidance emphasizes the need for accurate weighing of the animal for correct, weight-based administration.

Q: Are there warnings about Eraquell use for people with heart conditions?

A: Eraquell is a highly specialized veterinary product formulated exclusively for use in horses and is not for human use. Therefore, the official product label does not contain any information or warnings regarding its use for people with heart conditions.

Q: What interactions are listed for Eraquell and alcohol?

A: The official veterinary product label does not contain any statements regarding an interaction between Eraquell and alcohol. This product is restricted to use in horses and is not approved for consumption by people.

Q: Does Eraquell interact with common pain relievers like ibuprofen?

A: The veterinary label does not explicitly list interactions with pain relievers such as ibuprofen or similar over-the-counter medicines. Because official documents note the need for care when co-administering any medication, co-administration should be determined following consultation with a veterinarian.

Q: Are there any vitamins or supplements that interact with Eraquell?

A: Official labeling does not explicitly list interactions with vitamins or common nutritional supplements. However, because official documents note that using Eraquell alongside other substances requires caution, its combined use should be assessed by a veterinarian.

Q: Is the fatigue associated with Eraquell serious?

A: Lethargy (a form of fatigue) is a documented adverse event, particularly noted in cases of higher-than-recommended doses or in the context of neurotoxicity. Official documents indicate that observation of extreme or persistent lethargy warrants prompt reporting to a veterinarian.

Q: Is Eraquell a controlled substance?

A: According to government drug information, Eraquell, containing Ivermectin, is officially categorized as an OTC ANIMAL DRUG. It is not listed on any official controlled substance schedules.

Q: Are there any post-market studies for Eraquell?

A: Regulatory agencies continuously monitor the safety of approved products through post-market surveillance. This process collects and analyzes information about adverse effects seen outside of the clinical trial setting, using mandatory Adverse Event Reporting.

Q: Is it true that Eraquell should not be stopped suddenly?

A: Eraquell is typically a single-dose treatment for systemic parasite clearance, not a continuous daily or multi-day regimen that requires stopping. The treatment is considered complete upon administration, as guided by the parasite control cycle.

Q: Are there common misunderstandings about what Eraquell is used for?

A: Official public health agencies have issued statements and warnings to clarify the restricted use of this product. These communications ensure that this veterinary medicine is strictly not used for any human purposes or as a substitute for human-approved medications.

Q: Can you drive while taking Eraquell?

A: Eraquell is a veterinary product restricted to oral use in horses only and is not for human consumption. The official label does not provide any warnings or advice on human activities such as driving.

Q: Does Eraquell affect the effectiveness of birth control?

A: The product is for Oral Use in Horses Only and is Not for use in humans. Consequently, the official veterinary label does not contain information related to human medications like hormonal birth control.

Q: What should I know about discontinuing Eraquell use?

A: As Eraquell is generally a single-dose treatment, the concept of discontinuation is not applicable in the way it is for continuous human medications. The subsequent timing for treatment is determined by the strategic parasite control program.

Q: Do generic versions of Eraquell work the same way as the brand name?

A: Legally marketed generic products containing Ivermectin are required to meet official regulatory standards. These standards mandate that generic versions contain the same active ingredient at the same strength and follow equivalent official requirements for absorption and administration in the target species.

Q: Is it normal to feel a certain way when first starting Eraquell?

A: Official documentation focuses on listing adverse events that are possible in the target species, such as transient lethargy or depression. It does not provide guidance on subjective feelings or what is considered 'normal' for the animal immediately after treatment.

Q: Can Eraquell affect sleep patterns?

A: The label notes that adverse reactions include Nervous System Disorders, such as depression and lethargy, particularly at higher doses. It is possible that changes to overall sleep or wakefulness patterns may be connected to these documented central nervous system effects.

How should Eraquell be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal guidelines for Eraquell are mandated by regulatory authorities to ensure product stability and environmental safety.

Storage Conditions

  • Temperature: The Oral Paste must not be stored above 30 C.
  • Packaging: Store the Oral Paste in its original container. Chewable Tablets are packaged with a child-proof cap.

Stability and Shelf-Life

  • Oral Paste: The shelf-life after first opening the container is 6 months.
  • Chewable Tablets: The shelf-life after first opening the immediate packaging is 12 months.

Disposal Instructions

  • Environmental Hazard: The active substance is extremely dangerous to fish and aquatic life. It is strictly required not to contaminate surface water or ditches with the product or used containers.
  • Waste Management: Any unused veterinary product or derived waste material must be disposed of in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eraquell found in:

A-Z Index: